

Xiaofei Zhou

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7333394/xiaofei-zhou-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

517
citations

10
h-index

22
g-index

24
ext. papers

588
ext. citations

3.4
avg, IF

2.9
L-index

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 21 | Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. <i>Journal of Clinical Oncology</i> , 2014 , 32, 44-50 | 2.2 | 165 |
| 20 | Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2012 , 127, 63-9 | 4.9 | 114 |
| 19 | Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2014 , 32, 489-99 | 4.3 | 61 |
| 18 | Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. <i>Investigational New Drugs</i> , 2014 , 32, 1181-7 | 4.3 | 32 |
| 17 | Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib). <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2170-83 | 6.1 | 27 |
| 16 | Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 336-47 | 7.9 | 22 |
| 15 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015 , 33, 942-53 | 4.3 | 20 |
| 14 | Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2018 , 36, 248-258 | 4.3 | 12 |
| 13 | Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 35-51 | 3.8 | 10 |
| 12 | Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. <i>Drugs in R and D</i> , 2016 , 16, 45-52 | 3.4 | 10 |
| 11 | Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2568-2579 | 3.8 | 8 |
| 10 | Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015 , 53, 563-72 | 2 | 7 |
| 9 | Biotransformation Pathways and Metabolite Profiles of Oral [C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 217-229 | 4 | 6 |
| 8 | Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1464-1473 | 3.8 | 4 |
| 7 | Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2018 , 36, 240-247 | 4.3 | 4 |
| 6 | Abstract B216: Mass balance, routes of excretion and pharmacokinetics of investigational oral [14C]alisertib (MLN8237) in patients with advanced solid tumors or lymphoma. 2013 , | | 4 |
| 5 | Phase I study assessing the mass balance, pharmacokinetics, and excretion of [C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021 , 39, 488-498 | 4.3 | 4 |

| | | | |
|---|--|-----|---|
| 4 | Mass balance, routes of excretion, and pharmacokinetics of investigational oral [C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019 , 37, 666-673 | 4.3 | 3 |
| 3 | Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. <i>Clinical and Translational Science</i> , 2021 , 14, 1069-1081 | 4.9 | 3 |
| 2 | Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1204-1215 | 2.9 | 0 |
| 1 | Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational AuroraA kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2597-2597 | 2.2 | |